Sun Yat-sen University Cancer Center
Sun Yat-sen University Cancer Center is one of China's largest cancer centres, the global leader in nasopharyngeal carcinoma and a top enroller for Chinese ADC and PD-1 trials.
Nasopharyngeal carcinoma standards (Ma Jun), toripalimab and camrelizumab trials, iza-bren and other ADC trials.
- Nasopharyngeal carcinoma
- ADC and IO trials
A GI oncologist whose work on immunotherapy biomarkers and Chinese gastric cancer trials feeds global guidelines.
Jun Ma is the world's leading nasopharyngeal carcinoma trialist, whose randomised studies define induction chemotherapy and immunotherapy for the disease.
Led the Chinese trials of PD-1 blockade in nasopharyngeal and lung cancer and the early studies of the EGFR×HER3 bispecific ADC iza-bren.
Virologist who mapped how Epstein-Barr virus drives nasopharyngeal cancer and is developing vaccines against it.
Leads China's largest cancer centre and has run the Chinese phase 3 trials that brought PD-1 antibodies into GI cancer.
Wenfeng Fang is a lung cancer oncologist at the centre of China's PD-1 and bispecific antibody trials, including ivonescimab in EGFR-mutant disease.